Ultrasmall Chemogenetic Tags with Group‐Transfer Ligands

V Vedagopuram Sreekanth (Chemical Biology and Therapeutics Science) S Shaimaa H. Sindi (Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA) S Santosh K. Chaudhary (Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA) R Rajaiah Pergu (Chemical Biology and Therapeutics Science) P Prashant Singh (Ames National Laboratory) E Endri Karaj (Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA) S Surached Siriwongsup (Department of Cancer Biology) J Jeffrey E. Fung (Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA) A Arghya Deb (Department of Chemistry, Merkert Chemistry Center) S Stephan J. DeCarlo (Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA) J Jaron A. M. Mercer K Kei Yamada D Diego Rodriguez (Division of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s and Massachusetts General Hospitals (Mass General Brigham)) D David R. Liu A Amit Choudhary (Chemical Biology and Therapeutics Science)

Abstract

Abstract Chemogenetic tags facilitate exploration of activities of a protein‐of‐interest (POI) that lacks small‐molecule ligands; however, most tags are too large for several POIs. Here, we report two ultrasmall chemogenetic tags (mgTag and cTag) of 36 and 50 amino acids (aa) that, to the best of our knowledge, are the smallest. These tags exhibit transferase ‐type reactivity with their ligands, allowing the attachment of any moiety‐of‐interest to the tag. cTag utilizes an engineered C1 domain‐bearing cysteine that undergoes a group‐transfer reaction with its ligand. Likewise, mgTag utilizes an engineered zinc‐finger domain‐bearing cysteine that undergoes a group‐transfer reaction with its molecular glue ligand in the presence of cereblon (CRBN). While the fusion of HaloTag (297 aa) or SNAPTag (182 aa) to the KRAS G12D (188 aa) disrupted its growth‐signaling pathway, fusion of mgTag or cTag did not, pointing to the importance of tag size. Group‐transfer of BRD4 binder to tags appended to Abelson kinase (ABL) induced proximity between ABL and BRD4, resulting in the latter's phosphorylation. Deletion of the transferase ‐type reactivity reduced phosphorylation levels, suggesting that proximity‐inducing chimeras with group‐transfer design may be more efficacious. We envision these ultrasmall tags to have wide‐ranging applications, including in basic science, biotechnology, and medicine.

Article Details

Volume / Issue Vol. 64, Issue 44
Published October 27, 2025
ISSN 1433-7851
Publisher Wiley

Journal Info

Angewandte Chemie International Edition

Wiley

ISSN: 1433-7851 Physical Sciences

Authors (15)

V

Vedagopuram Sreekanth

Chemical Biology and Therapeutics Science

S

Shaimaa H. Sindi

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

S

Santosh K. Chaudhary

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

R

Rajaiah Pergu

Chemical Biology and Therapeutics Science

P

Prashant Singh

Ames National Laboratory

E

Endri Karaj

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

S

Surached Siriwongsup

Department of Cancer Biology

J

Jeffrey E. Fung

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

A

Arghya Deb

Department of Chemistry, Merkert Chemistry Center

S

Stephan J. DeCarlo

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

J

Jaron A. M. Mercer

K

Kei Yamada

D

Diego Rodriguez

Division of Movement Disorders Harvard Biomarkers Study 2.0 (HBS 2.0) and MyTrial Programs, American Parkinson Disease Association, Center for Advanced Research and MSA Center of Excellence, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s and Massachusetts General Hospitals (Mass General Brigham)

D

David R. Liu

A

Amit Choudhary

Chemical Biology and Therapeutics Science